NIH FY11 Budget On The Chopping Block?

By Bouvier Grant Group

We stay current on NIH happenings and would be delighted to keep you informed.

As the White House and House Republicans continue to negotiate toward a Thursday deadline for an FY11 budget to fund the final six months of the year, it appears that NIH may be on the chopping block. Rumors are all over the place and no definitive information seems to be available. An earlier Senate budget plan would have maintained NIH funding at its FY10 level. But with $38 billion to cut from the budget, any nondefense discretionary spending is at risk.

While I hesitate to link to an article from a partisan journal like The Nation without balancing it with other viewpoints, alas there is little definitive news arising from the murky depths of “budget negotiation hell” this week. So with that caveat, I encourage you to take a look at this article in The Nation.

The author states that NIH’s $31B annual budget accounts for one-third of the Department of Health and Human Services discretionary spending. She argues that cutting the budget would not make a meaningful dent in the budget deficit, as NIH only accounts for 2.9% of total discretionary spending.

Research funded through NIH extramural funds would not be supported by other sources. For-profit companies will develop promising research through R&D, but basic science funding must first get a project to the point where it shows enough promise to be developed.

The author goes on to say that if there were cuts, “The NCI will prioritize funding the same level of new grants (they currently fund 14 percent of new grant applications), but will have to cut funding from cancer centers. Others will have to choose between new and existing grants. When ongoing grants aren’t renewed, work may simply stop.” The fear is that we will lose the best and brightest scientists to industry, other fields, and/or other countries with a less draconian funding climate.

She states further, “Funding ‘basic science’ doesn’t sound appealing in lean-budget times, but cutting research in times of economic woe is counterproductive. Nearly 90 percent of the NIH research budget gets distributed across the country, employing scientists and lab technicians.”

Need I add that we as a nation spend billions of dollars each year treating preventable diseases? I recently blogged about the upcoming Community Transformation Grants, which target such diseases. It is funded through the Affordable Care Act, all aspects of which are at-risk for funding cuts– which seems economically short-sighted to me.

The author of the article concludes with the compelling statistic that each year 300,000 people die of cancer, which is the equivalent of losing 3,000 people in the Twin Towers every other day. She encourages those who support traditional defense spending to consider which enemy poses the greatest threat, and asserts that biomedical research is our best defense.

Many groups are organizing campaigns to oppose possible NIH budget cuts. For example, the Pancreatic Cancer Action Network has organized a Facebook page to “Help Oppose NIH Budget Cuts” And many biomedical research groups and foundations are encouraging members to contact their senators and representatives.

I know I posted this quote in support of basic science research recently, but given the circumstances this week I feel it bears repeating:

“None of the most important weapons transforming warfare in the 20th century- the airplane, tank, radar, jet engine, helicopter, electronic computer, not even the atomic bomb- owed its initial development to a Doctrinal Requirement or request of the military.”

John Chambers, ed. The Oxford Companion to American Military History (New York, Oxford University Press, 1999 p. 79.)

Author:
Dr. Meg Bouvier

Margaret Bouvier received her PhD in 1995 in Biomedical Sciences from the Mount Sinai School of Medicine. After an NINDS post-doctoral fellowship, she worked as a staff writer for long-standing NIH Director Dr. Francis Collins in the Office of Press, Policy, and Communications for the Human Genome Project and NHGRI. Since 2007, Meg has specialized in editing and advising on NIH submissions, and began offering virtual courses in 2015. She's recently worked with more than 40% of the nation's highest-performing hospitals*, four of the top 10 cancer hospitals, three of the top five medical schools for research, and 14 NCI-designated cancer centers. Her experience at NIH as both a bench scientist and staff writer greatly informs her approach to NIH grantwriting. She has helped clients land over half a billion in federal funding. Bouvier Grant Group is a woman-owned small business.

*Our clients include 9 of the top 22 hospitals as recognized by the 2023/24 US News & World Report honor roll

Categories:
Related posts

You May Also Be Interested In

We read all NIH notices for our clients. When you join our mailing list, we’ll pass along important changes directly to your inbox, as well as opportunities to improve your grantsmanship skills.
Primary Position
Lead Source

Wait!

Subscribe to our monthly newsletter for the latest NIH news, grantwriting tips, and more.

NIH-October-2023-Newsletter